Caribou Biosciences, Inc
2929 7th Street
Suite 150
Berkeley
California
94710
United States
Tel: 510-982-6030
68 articles with Caribou Biosciences, Inc
-
The European Hematology Association’s 2022 Hybrid Congress is in full swing in Vienna, Austria and will feature the newest and most promising developments in blood cancer research.
-
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
5/12/2022
Caribou Biosciences, Inc. announced initial results demonstrating a 100% overall response rate and 80% complete response rate in cohort 1 from its ANTLER Phase 1 trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
-
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
4/25/2022
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the European Hematology Association (EHA) has accepted an abstract with initial clinical data from Caribou’s ongoing ANTLER Phase 1 trial of CB-010 for the EHA 2022 Hybrid Congress, being held in Vienna, Austria, June 9-12, 2022.
-
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
4/8/2022
Caribou Biosciences, Inc. announced the presentation of positive preclinical data for its allogeneic, immune-cloaked, anti-BCMA CAR-T cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma.
-
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
3/8/2022
Caribou Biosciences, Inc. (Nasdaq: CRBU), today announced that preclinical data from CB-011, its allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma (r/r MM), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022 in New Orleans.
-
The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to Broad, not UC Berkeley.
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
BioSpace Movers & Shakers, Nov. 12
11/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
-
DA32 Life Science SPAC Prices $200M IPO
7/28/2021
Deerfield Management and ARCH Venture Partners have partnered with venture capital firm Section 32 to sponsor DA32 Life Science Tech Acquisition Corp, a blank check company that is today priced for $200 million in an initial public offering (IPO). -
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
7/27/2021
Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share.
-
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
7/23/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share.
-
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
7/12/2021
Caribou Biosciences, Inc. announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial ( NCT04637763 ) to evaluate the company’s lead product candidate, CB-010.
-
Money on the Move: June 30 – July 6
7/7/2021
The long weekend didn't slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. -
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
6/22/2021
Caribou Biosciences, Inc. announced today that it has appointed Scott Braunstein, M.D. to its board of directors.
-
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson's disease and other neurodegenerative conditions.
-
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board
5/17/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has expanded its scientific advisory board (SAB) with the appointment of two new members: Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center; and Christopher Sturgeon, Ph.D.,
-
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors
5/5/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Andrew Guggenhime to its board of directors. Mr. Guggenhime is an accomplished biopharmaceutical industry leader with more than 20 years of experience.
-
The company’s overarching aim is to edit and equip cells with molecular tools, through CRISPR, to eliminate certain cancers.